In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies
Clinical trial NCT01430390 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT01430390
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2011-09-01
- Primary completion
- 2026-09-01
- Enrollment
- 19
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.